What is the recommended dosing and administration of Lexapro (escitalopram) for adults with major depressive disorder or generalized anxiety disorder?

Lexapro (Escitalopram) Dosing and Administration

For adults with major depressive disorder or generalized anxiety disorder, start Lexapro at 10 mg once daily, which can be increased to a maximum of 20 mg daily after at least 1 week if needed, though 10 mg is often sufficient for most patients. 1

Dosing by Indication

Major Depressive Disorder (MDD)

Adults:

• Starting dose: 10 mg once daily 1
• Dose adjustment: May increase to 20 mg daily after minimum 1 week interval based on clinical response 1
• Key consideration: Fixed-dose trials showed both 10 mg and 20 mg were effective, but failed to demonstrate greater benefit of 20 mg over 10 mg 1
• Clinical insight: Research suggests 10 mg is optimal for moderate depression, while 20 mg may be needed for severe depression (MADRS ≥30) 2

Adolescents (12 years and older):

• Starting dose: 10 mg once daily 1
• Dose adjustment: May increase to 20 mg daily after minimum 3 weeks (note the longer interval than adults) 1

Generalized Anxiety Disorder (GAD)

Adults:

• Starting dose: 10 mg once daily 1
• Dose adjustment: May increase to 20 mg daily after minimum 1 week interval 1
• Evidence base: Multiple pooled trials demonstrate efficacy at 10 mg, with significant improvement beginning at week 1-2 3, 4

Children and Adolescents (7 years and older):

• Starting dose: 10 mg once daily 1
• Dose adjustment: May increase to 20 mg daily after minimum 2 weeks 1

Administration Details

• Timing: Once daily, morning or evening (patient preference) 1
• Food: With or without food 1
• Formulation: Available as tablets and oral drops 5

Special Populations

Elderly patients:

• Recommended dose: 10 mg once daily (do not routinely increase) 1

Hepatic impairment:

• Recommended dose: 10 mg once daily 1

Renal impairment:

• Mild to moderate: No adjustment needed 1
• Severe (CrCl <20 mL/min): Dosing not established 1

Critical Monitoring and Management

Initial Monitoring

Begin monitoring within 1-2 weeks of initiation for suicidal thoughts/behaviors, therapeutic response, and adverse effects 6, 1. This early monitoring is particularly crucial in the first 1-2 months when suicide risk is highest 6.

Response Assessment Timeline

• Assess response at 6-8 weeks: If inadequate response, modify treatment 6
• Early improvement: Anxiety symptoms may improve as early as week 1-2 3, 4
• Depression improvement: Typically requires 2-4 weeks for moderate depression, up to 4 weeks for severe depression 2

Duration of Treatment

After achieving satisfactory response 6:

• First episode MDD: Continue 4-9 months 6
• Recurrent depression (≥2 episodes): Consider longer duration (years to lifelong) 6
• GAD maintenance: 20 mg daily significantly reduces relapse risk in responders 7

Discontinuation Protocol

Never stop abruptly. Gradual dose reduction is essential to minimize discontinuation symptoms 1. While escitalopram has relatively low discontinuation syndrome risk compared to shorter-acting SSRIs like paroxetine 8, symptoms can include:

• Dizziness (10-12%)
• Nervousness (2-6%)
• Insomnia (2-6%)
• Sensory disturbances 8, 7

If intolerable symptoms occur during taper, resume previous dose and decrease more gradually 1.

Drug Interactions and Contraindications

Absolute contraindication: MAOIs - allow 14 days between discontinuing MAOI and starting escitalopram, or vice versa 1

Favorable interaction profile: Escitalopram/citalopram have the least effect on CYP450 isoenzymes compared to other SSRIs, resulting in lower propensity for drug-drug interactions 8

QT prolongation: While citalopram requires caution above 40 mg daily, escitalopram has not shown the same degree of concern at therapeutic doses 8

Pre-Treatment Screening

Screen for bipolar disorder before initiating treatment - assess personal and family history of bipolar disorder, mania, or hypomania 1. Antidepressants can precipitate manic episodes in undiagnosed bipolar disorder 9.

Common Pitfalls to Avoid

1. Don't automatically escalate to 20 mg - 10 mg is often sufficient, particularly for moderate depression and GAD 1, 2
2. Don't increase dose before adequate trial duration - allow minimum intervals (1 week for adults with MDD/GAD, 2-3 weeks for pediatrics) 1
3. Don't discontinue abruptly - always taper gradually 1
4. Don't forget early monitoring - assess within 1-2 weeks for suicidality and adverse effects 6, 1
5. Don't give up too early - allow 6-8 weeks before declaring treatment failure 6